Abstract
1223PD - Quality-adjusted survival of combined nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone vs IPI among treatment-naïve patients (pts) with advanced melanoma (MEL): a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have